Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Definitely not small fish like you and me.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Dan88 Member Profile
 
Followed By 34
Posts 1,017
Boards Moderated 0
Alias Born 08/12/14
160x600 placeholder
Immune Therapeutics, Inc. Spinoff Cytocom, Inc. Appoints BioPharm Industry Veteran as New Chief Operating Officer InvestorsHub NewsWire - 11/11/2020 9:11:00 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/10/2020 4:58:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/2/2020 2:16:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/16/2020 6:59:18 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/13/2020 9:31:10 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/15/2020 5:14:31 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2020 3:24:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2020 4:52:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 4:44:16 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/12/2020 4:12:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:10:20 PM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2020 5:28:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 4:41:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/27/2020 2:47:39 PM
Dan88   Friday, 09/18/20 06:33:35 PM
Re: kabunushi post# 308987
Post # of 333649 
Definitely not small fish like you and me. Use your imagination. Most who have done their DDs think DCVax-L Phase 3 trial for GBM will be successful, meaning FDA approvable, but there are some who think otherwise.

Some of those who think otherwise have been much more resourceful and bold, let alone they may have other agenda other than making money.

The trading history and pattern of deteriorating endless dilutions in the past tell the story; AF, the never ending forces who have turned good news into bad; the few proliferate posters who have never ever said a single word good about the company; our own SV Les who despite unlikable by many who have talked with him has repeatedly claimed hundred of millions of naked short shares; and CDEL if you watch trading everyday which has been in the ask with lower price at any opportunist times with 100 share lots when volumes are low and recently 1000 share lots when volumes increase.

Yes anybody's selling order may be directed to CDEL or any other MMs, but its strange lots and never ending lowest ask price, meticulously and painstakingly opportunistic timing tell a story: you would think CDEL likes to lose money, right? It has definitely lost a lot of money when share price has been appreciated in recent months from low 20 cents to today's 80 cents, and CEDL has been always at the lowest ask. Even a rock know CEDL has been losing money for fun, and yes CEDL never adjusts. Does that tell a story of naked shorting and stubbornness.

No point to argue, we will know soon enough when Topline data is announced.

Most people don't believe, but it's actually very prevalent for hedge funds to have significant naked short positions in most small biotech companies in the face of a binary event regardless what the share prices are.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences